Bria-OTS™
Recently awarded Fast Track status by the U.S. Food and Drug Administration (FDA), BriaCell is developing Bria-IMT™ in combination with immune checkpoint inhibitors in a clinical trial listed in ClinicalTrials.gov as NCT03328026. BriaCell is currently enrolling and dosing advanced breast cancer patients in its Phase I/IIa combination study of Bria-IMT™ with Incyte’s checkpoint inhibitor, retifanlimab, and its immunomodulator, epacadostat under a corporate collaboration with Incyte.
Bria-OTS™: Off-the-Shelf Personalized Immunotherapy
- We believe our cellular immunotherapy is most effective when the patient’s HLA-type matches the Bria-IMT™ HLA-type.
- We are engineering 15 unique HLA types (molecules) into Bria-IMT™, collectively referred to as Bria-OTS™, allowing for matching of over 99% of patients with advanced breast cancer.
- A simple saliva test is used to determine the HLA-type of each patient.
- Each patient will then be treated with the appropriate pre-manufactured Bria-OTS™ formulation.
- Similar cell lines are in development for prostate cancer, lung cancer, and melanoma.
- A pre-clinical Cooperative Research and Development Agreement (CRADA) is in place with the National Cancer Institute (NCI) in the U.S. to investigate the Bria-OTS™ mechanism of action.
- This approach allows personalized treatment without the need for personalized manufacturing. Additionally, it saves time and skips expensive and complicated manufacturing procedures associated with other personalized immunotherapy treatments.
Bria-OTS™: Off-the-Shelf Personalized Immunotherapy
BRIA-OTS™ IMMUNOTHERAPY COVERS ~99% OF THE BREAST CANCER POPULATION
